MedTrace Logo

Administration of BIIB028 to Subjects With Solid Tumors

NCT00725933 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-01-09

No results posted yet for this study

Summary

Safety and Tolerability of BIIB028

Conditions

Interventions

DRUG

BIIB028

IV infusion administered twice weekly until disease progression or unacceptable toxicity

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725933 on ClinicalTrials.gov